Spanish Covid-19 vaccine shows high efficacy against Omicron variants
1st Feb 2022 13:22
(Sharecast News) - The Covid-19 vaccine being developed by Spain's Hipra has shown a "high efficacy" against the new Omicron variants and is now entering third phase clinical trials.
Read moreOmicron subvariant is 1.5 times more transmissible than original
31st Jan 2022 10:58
(Sharecast News) - A new Omicron subvariant known is more transmissible than its forebear which first appeared in South Africa, scientists said at the weekend, although some studies have shown that vaccines are more effective against it.
Read moreMorgan Stanley reiterates 'buy' for FTSE 100, highlights 'defensive' qualities
24th Jan 2022 12:13
(Sharecast News) - Analysts at Morgan Stanley sounded a 'bullish' note on the outlook for the FTSE 100, highlighting its greater 'defensive' properties relative to rivals, higher dividend yields versus global peers, exposure to energy and record low expectations for growth in the profits of its constituent companies.
Read moreAstraZeneca reports positive results from Imfinzi trials
19th Jan 2022 07:55
(Sharecast News) - AstraZeneca on Wednesday said its Imfinzi drug combined with chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC) after results from a phase III clinical trial.
Read moreAstraZeneca's Enhertu granted priority review by US FDA
17th Jan 2022 07:38
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Daiichi Sankyo collaboration Enhertu had been granted priority review by the Federal Drug Administration in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.
Read moreAstraZeneca strikes collaboration and license agreement with Neurimmune
7th Jan 2022 07:07
(Sharecast News) - Drugmaker AstraZeneca's Alexion rare diseases unit has inked an exclusive collaboration and license agreement with Neurimmune that will see the pair develop and commercialise NI006, an investigational human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy.
Read moreAstraZeneca, Ionis close eplontersen deal
29th Dec 2021 07:34
(Sharecast News) - AstraZeneca said on Wednesday that it has closed a global development and commercialisation agreement with California-based Ionis Pharmaceutical for eplontersen, a medicine used in the treatment of transthyretin amyloidosis.
Read moreAstraZeneca neuromuscular treatment gets US priority review
21st Dec 2021 07:29
(Sharecast News) - AstraZeneca on Tuesday said its neuromuscular treatment had been accepted for priority review in the US.
Read moreAstraZeneca-Amgen asthma drug gets US approval
20th Dec 2021 07:42
(Sharecast News) - The AstraZeneca-Amgen asthma drug Tezspire has been approved by the US Food and Drug Administration to treat of adult and paediatric patients aged 12 years and older, the two companies said on Monday.
Read moreAstraZeneca lupus treatment wins EU marketing approval
20th Dec 2021 07:21
(Sharecast News) - AstraZeneca's lupus treatment has received marketing authorisation by the European Union, the company said on Monday.
Read moreOmicron results in fewer hospitalisations and ICU admissions, SA study shows
14th Dec 2021 09:57
(Sharecast News) - The newest variant of the SARS-CoV-2 coronavirus has resulted in fewer hospitalisations and intensive care unit admissions than previous waves of Covid-19, the results of a new study show.
Read moreBerenberg slightly lowers target price on AstraZeneca
10th Dec 2021 10:46
(Sharecast News) - Analysts at Berenberg slightly lowered their target price on drugmaker AstraZeneca from 105.0p to 100.0p on Friday but said they were "optimistic" about the firm's pipeline destiny.
Read moreFDA grants emergency use for AstraZeneca's Covid-19 preventative
9th Dec 2021 07:55
(Sharecast News) - AstraZeneca said on Thursday that its Evusheld antibody combination has been granted emergency use authorisation by the US Food and Drug Administration for the prevention of Covid-19 in adults and adolescents who are immunocompromised.
Read moreAstraZeneca strikes development and commercialisation deal with Ionis
7th Dec 2021 07:45
(Sharecast News) - Drugmaker AstraZeneca has struck a deal with Ionis Pharmaceuticals that will see the pair work together to develop and commercialise its investigational medicine Eplontersen.
Read moreTwo Hutchmed drugs included in China's 2022 reimbursement list
3rd Dec 2021 13:23
(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.
Read more